Anavex Life Sciences (AVXL) Common Equity (2010 - 2025)
Anavex Life Sciences (AVXL) posted Common Equity of $126.6 million for Q4 2025, up 33.47% sequentially from $94.9 million in Q3 2025, and up 14.16% YoY from $110.9 million in Q4 2024.
Anavex Life Sciences (AVXL) Common Equity (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Common Equity for 16 years, with the latest figure at $126.6 million in Q4 2025.
- Quarterly Common Equity rose 14.16% year-over-year to $126.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $126.6 million (up 14.16% YoY) and the FY2025 annual result came in at $94.9 million, down 21.12% from the prior year.
- Common Equity grew to $126.6 million in Q4 2025 per AVXL's latest filing, from $94.9 million in the prior quarter.
- Over five years, Common Equity peaked at $157.1 million in Q2 2021 and troughed at $75.8 million in Q1 2021.
- A 5-year average of $129.4 million and a median of $135.3 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity surged 536.71% in 2021, then retreated 29.91% in 2025.
- Over 5 years, Common Equity stood at $146.4 million in 2021, then slipped by 7.68% to $135.1 million in 2022, then advanced by 0.33% to $135.6 million in 2023, then slipped by 18.19% to $110.9 million in 2024, then increased by 14.16% to $126.6 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $126.6 million, $94.9 million, and $91.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 126.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126.62 Mn |
| Sep 30, 2025 | 94.87 Mn |
| Jun 30, 2025 | 90.96 Mn |
| Mar 31, 2025 | 99.76 Mn |
| Dec 31, 2024 | 110.92 Mn |
| Sep 30, 2024 | 120.26 Mn |
| Jun 30, 2024 | 129.78 Mn |
| Mar 31, 2024 | 134.96 Mn |
| Dec 31, 2023 | 135.58 Mn |
| Sep 30, 2023 | 141.85 Mn |
| Jun 30, 2023 | 146.76 Mn |
| Mar 31, 2023 | 145.17 Mn |
| Dec 31, 2022 | 135.12 Mn |
| Sep 30, 2022 | 142.49 Mn |
| Jun 30, 2022 | 150.74 Mn |
| Mar 31, 2022 | 152.21 Mn |
| Dec 31, 2021 | 146.37 Mn |
| Sep 30, 2021 | 150.82 Mn |
| Jun 30, 2021 | 157.15 Mn |
| Mar 31, 2021 | 75.81 Mn |